SCHEMBL13604903

SCHEMBL13604903

CC(C)(C)c1cc2[nH]ccc2nc1C(C)(C)C

nearest known ligand 0.33

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ CYP3A4 P08684 2/20 0.33
▸ KCNH2 Q12809 1/20 0.32
▸ SCN10A Q9Y5Y9 1/20 0.32
▸ BRD4 O60885 1/20 0.31
▸ APP P05067 1/20 0.31
▸ CYP1A2 P05177 1/20 0.30
▸ MAPT P10636 1/20 0.30
▸ CYP2C19 P33261 1/20 0.30
▸ RAB9A P51151 1/20 0.30
▸ IMPDH2 P12268 1/20 0.30
▸ IMPDH1 P20839 1/20 0.30
▸ MEN1 O00255 1/20 0.30
▸ POLB P06746 1/20 0.30
▸ MAPK1 P28482 1/20 0.30
▸ KMT2A Q03164 1/20 0.30
▸ CYP2A6 P11509 1/20 0.30
▸ NPC1 O15118 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21672437 0.84 BRD4 (0.38) CYP3A4KCNH2SCN10ABRD4APP
SCHEMBL21672428 0.81 AHR (0.35) CYP3A4KCNH2SCN10ABRD4APP
SCHEMBL22792806 0.78 APP (0.32) CYP3A4SCN10AAPPMEN1POLB
SCHEMBL13604904 0.73 CDK8 (0.39) BRD4
SCHEMBL8957480 0.71 GPR84 (0.48) CYP3A4CYP1A2MAPTCYP2C19RAB9A
SCHEMBL14104385 0.69 MAPK1 (0.41) MAPK1
SCHEMBL18118981 0.69 ALDH1A1 (0.39) CYP1A2MAPTCYP2C19POLB
SCHEMBL15102107 0.68 CCR4 (0.36) CYP3A4BRD4CYP1A2MAPTCYP2C19
SCHEMBL12132906 0.68 ALDH1A1 (0.48) CYP1A2MAPTRAB9APOLBKMT2A
SCHEMBL13604906 0.68 ALDH1A1 (0.38) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200392128-A1 NOVEL HETEROCYCLIC DERIVATIVES USEFUL AS SHP2 INHIBITORS JACOBIO PHARMACEUTICALS CO., LTD. (CN) 2020-12-17 — — US disclosed
US-7638530-B2 1-{1-[4-(3-amino-5-phenyl-1H-pyrazolo[3,4-b]pyridin-6-yl)benzyl]piperidin-4-yl}-1,3-dihydro-2H-benzimidazol-2-one; anticarcinogenic agents MERCK & CO., INC. (US) 2009-12-29 — — US disclosed
US-7638530-B2 1-{1-[4-(3-amino-5-phenyl-1H-pyrazolo[3,4-b]pyridin-6-yl)benzyl]piperidin-4-yl}-1,3-dihydro-2H-benzimidazol-2-one; anticarcinogenic agents MERCK & CO., INC. (US) 2009-12-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200392128-A1 NOVEL HETEROCYCLIC DERIVATIVES USEFUL AS SHP2 INHIBITORS PTPN5, PTPN1, PTPRJ CYP3A4 4643/4885KCNH2 4068/4885SCN10A 1766/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback